To get a pulse on the U.S.
Douglas Long, vice president of industry relations at Durham, NC-based IQVIA, a newly named company after the merger of IMS Health and Quintiles, discussed pharmaceutical marketplace trends during the headline session at the Academy of Ma
A diabetes patient’s ambivalence about changing their diet or taking their insulin can stand between successful management of their disease and a further escalation that could lead to blindness, limb removal, or even death.
Payers are stepping up efforts to manage the cost and utilization of orphan drug treatments.
The cost to treat cancer in the United States could reach $156 billion in 2020, according to the National Cancer Institute. And innovative medications have a significant impact on the cost of care.
Gene therapy, which got its start in the 1960s, is finally starting to take hold.
Expiring patents and biosimilar developments are creating big market opportunities within the specialty drug space.
High-cost treatments for rheumatoid arthritis has fueled the need to better understand their value to healthcare systems and patients.
Attending the AMCP Managed Care and Specialty Pharmacy Annual Meeting in Boston April 23 to April 26? Here are our top session recommendations.
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.